70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H2 2016

  • ID: 3989560
  • Report
  • 43 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • ArQule, Inc.
  • Astex Pharmaceuticals Inc
  • Eddingpharm
  • Merck KGaA
  • PharmAust Limited
  • Sentinel Oncology Limited
  • MORE
70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

‘70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.
Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
- The report reviews 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ArQule, Inc.
  • Astex Pharmaceuticals Inc
  • Eddingpharm
  • Merck KGaA
  • PharmAust Limited
  • Sentinel Oncology Limited
  • MORE
List of Tabless

List of Figures

-Introduction

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Overview

-Therapeutics Development

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Stage of Development

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Therapy Area

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Indication

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Products Glance

-Late Stage Products

-Early Stage Products

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Companies

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Therapeutics Assessment

-Assessment by Monotherapy/Combination Products

-Assessment by Mechanism of Action

-Assessment by Route of Administration

-Assessment by Molecule Type

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Companies Involved in Therapeutics Development

-ArQule, Inc.

-Astex Pharmaceuticals Inc

-Eddingpharm

-Merck KGaA

-PharmAust Limited

-Phoenix Biotechnology, Inc.

-Sentinel Oncology Limited

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drug Profiles

-AT-13148 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-EDP-317 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-M-2698 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-monepantel - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-PBI-05204 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Small Molecule To Inhibit S6K1 For Breast Cancer - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Small Molecules to Inhibit S6K for Oncology - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Dormant Projects

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Discontinued Products

-70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Featured News & Press Releases

-Jul 11, 2016: Juniper Pharma Successfully Completes Manufacture of Reformulated MPL Capsules

-Jan 29, 2016: PharmAust Limited Announced Quarterly Report & Company Update For the period ended 31 December 2015

-Nov 26, 2015: PharmAust Appoints GenScript to Complete Further Pre-Clinical Validation for Phase II Trial

-Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types

-Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types

-Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says

-Jan 22, 2010: ACT BIOTECH Announces FDA Acceptance Of IND For ACTB1003, A First-in-Class Anti-Cancer Therapeutic

-Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference

-Appendix

-Methodology

-Coverage

-Secondary Research

-Primary Research

-Expert Panel Validation

-Contact Us

-Disclaimer

List of Tabless

-Number of Products under Development for, H2 2016

-Number of Products under Development by Therapy Area, H2 2016

-Number of Products under Development by Indication, H2 2016

-Comparative Analysis by Late Stage Development, H2 2016

-Comparative Analysis by Early Stage Products, H2 2016

-Number of Products under Development by Companies, H2 2016

-Products under Development by Companies, H2 2016

-Assessment by Monotherapy/Combination Products, H2 2016

-Number of Products by Stage and Mechanism of Action, H2 2016

-Number of Products by Stage and Route of Administration, H2 2016

-Number of Products by Stage and Molecule Type, H2 2016

-Pipeline by ArQule, Inc., H2 2016

-Pipeline by Astex Pharmaceuticals Inc, H2 2016

-Pipeline by Eddingpharm, H2 2016

-Pipeline by Merck KGaA, H2 2016

-Pipeline by PharmAust Limited, H2 2016

-Pipeline by Phoenix Biotechnology, Inc., H2 2016

-Pipeline by Sentinel Oncology Limited, H2 2016

-Dormant Projects, H2 2016

-Discontinued Products, H2 2016

List of Figures

-Number of Products under Development for, H2 2016

-Number of Products under Development by Therapy Area, H2 2016

-Number of Products under Development by Indication, H2 2016

-Comparative Analysis by Early Stage Products, H2 2016

-Assessment by Monotherapy/Combination Products, H2 2016

-Number of Products by Stage and Mechanism of Actions, H2 2016

-Number of Products by Stage and Routes of Administration, H2 2016

-Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ArQule, Inc.
  • Astex Pharmaceuticals Inc
  • Eddingpharm
  • Merck KGaA
  • PharmAust Limited
  • Phoenix Biotechnology, Inc.
  • Sentinel Oncology Limited
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll